These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 12243636

  • 21. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.
    JAMA; 2006 Sep 13; 296(10):1242-8. PubMed ID: 16968848
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
    Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, Ibsen H, Kjeldsen SE, Dahlöf B.
    Hypertension; 2005 Sep 13; 46(3):492-9. PubMed ID: 16116047
    [Abstract] [Full Text] [Related]

  • 23. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlöf B, Devereux RB.
    Am J Hypertens; 2010 Jul 13; 23(7):786-93. PubMed ID: 20395941
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B.
    JAMA; 2004 Nov 17; 292(19):2350-6. PubMed ID: 15547162
    [Abstract] [Full Text] [Related]

  • 28. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.
    J Hypertens; 2012 Apr 17; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009 Apr 17; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 2000 Aug 17; 13(8):899-906. PubMed ID: 10950398
    [Abstract] [Full Text] [Related]

  • 35. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    Am J Hypertens; 2012 Oct 17; 25(10):1101-9. PubMed ID: 22717544
    [Abstract] [Full Text] [Related]

  • 36. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
    Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I.
    Pharmacogenet Genomics; 2010 Feb 17; 20(2):77-85. PubMed ID: 20065889
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH.
    J Hypertens; 2012 Jun 17; 30(6):1252-9. PubMed ID: 22499288
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.